the financial times and its journalism are subject to a self-regulation regime under the ft editorial code of practice:.

loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people..

"i can't think of anything else where we have done that medically," van den veyver said.....